Management Team

CASI’s senior management team is responsible for aligning the company’s business strategy with its core scientific strengths, while maintaining prudent resource management, fiscal responsibility and accountability.

Ken K. Ren, Ph.D. Dr. Ren joined CASI Pharmaceuticals in April 2012, was appointed Chief Executive Officer in April 2013, and was elected to the Board of Directors in December 2014. Over the past 15 years, prior to CASI, Dr. Ren has been a founder and/or key executive in several start-up companies with business operations in both the U.S. and China. He was President of Accelovance (China), a clinical contract research organization, a co-founder and CEO of ImmunoVentis, a cell-based immunotherapy company, Novemed, a drug development company, and of China Innovation Center for Life Science (U.S.A.) Corp., a consulting company. Dr. Ren was also a Chief Investment Director of CCBI Healthcare Fund of China Construction Bank, responsible for private equity investment in China’s healthcare industry. Dr. Ren was a research scientist at Pfizer from 1993–1995 and an Immunology Research Fellow at Rockefeller University from 1990–1993. He received his medical degree at the Shandong University School of Medicine in China in 1986 and a Ph.D. in immunology from the State University of New York at Buffalo in 1990 and a Certificate of Completion of Executive Business Management Program in Tsinghua University, Beijing China.

Larry Zhang Mr. Zhang joined CASI Pharmaceuticals in September 2018 as President of CASI (Beijing) Pharmaceuticals Co., Ltd., which is a subsidiary of CASI Pharmaceuticals, and has more than 20 years management experience in the healthcare and biopharmaceutical industries in the U.S., Asia Pacific, and China. Prior to joining CASI’s Beijing office, Mr. Zhang was Vice President, Head of Public Affairs and Corporate Responsibly at Novartis Group (China) focusing on the public affairs/public relations strategy including initiating Novartis’ China policy focusing on China FDA (CFDA) new drug approval reform, IP protection, generic quality consistency evaluation and new regulations on biosimilars. From 2011-2016, he was Chief Executive Officer of Sandoz Pharmaceutical (China), a Novartis Company. Dr. Zhang has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific. He holds a bachelor and master degree in nuclear physics from University of Science & Technology of China, an MBA in marketing/finance from the University of California at Los Angeles (UCLA), and received Ph.D. training in political science from University of Utah.

George Chi, CPA, CFA Mr. Chi joined CASI Pharmaceuticals in October 2018 as Chief Financial Officer. Prior to joining CASI, Mr. Chi was Vice President of Finance at Flavors Holdings where he led the global accounting function, including financial reporting, planning, treasury, investor relations, tax and auditing with global sales in 90 countries. Prior to Flavor Holdings, from 2014-2016, he was Chief Financial Officer at BPL Plasma delivering 60% sales growth and 300% EBITDA growth for a $180 million business. He consolidated business and finance operations to prepare for an IPO where the business was sold four times of the investment in three years. From 2008-2013, he was finance director at Unilever where he was responsible for leading the accounting function including financial reporting, annual budgeting and strategic planning for a $10 billion business across 12 categories. He also successfully managed a $12 billion debt portfolio and coordinate with investment banks for annual debt issuance and repayment. Mr. Chi holds a bachelor’s degree in engineering from Tsinghua University, Beijing, China and a M.B.A. in finance and operations from the Yale School of Management. He also holds certifications as a CPA, CFA from Stanford University Risk Management.

Cynthia W. Hu, JD. Ms. Hu joined CASI Pharmaceuticals in June 2006 as Vice President, General Counsel & Secretary, and in December 2008 was appointed Chief Operating Officer. Prior to joining CASI Pharmaceuticals, from January 2000 to May 2006, Ms. Hu served as senior attorney for the corporate and finance practice group at Powell Goldstein LLP in Washington, DC, where she advised clients on all corporate and financing matters, including complex public and private financings, mergers and acquisitions, SEC and regulatory compliance, and corporate governance and compliance. Before that, Ms. Hu served as corporate and securities counsel for a NYSE-listed financial institution and prior to that was in private practice with increasing levels of responsibilities, including at Klehr, Harrison, Harvey & Branzburg, LLP and Littman & Krooks, LLP focusing on corporate transactions and compliance with corporate and securities laws.

Alexander A. Zukiwski, M.D. Dr. Zukiwski joined CASI Pharmaceuticals in April 2017 as Chief Medical Officer. Prior to joining CASI Pharmaceuticals Dr. Zukiwski was Chief Executive Officer and Chief Medical Officer of Arno Therapeutics and has been a Director of Arno Therapeutics since 2014. At Arno his responsibilities included leading the clinical development and regulatory affairs teams to support the company’s pipeline. Prior to Arno in 2007, Dr. Zukiwski served as Chief Medical Officer and Executive Vice President of Clinical Research at MedImmune. Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson’s (J&J,) medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development LLC (J&JPRD); Centocor R&D and Ortho Biotech. Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer. Dr. Zukiwski has more than 21 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere®, Xeloda®, Procrit®/Eprex®, Velcade®, Yondelis®, and Doxil®. He previously served as a Member of Medical Advisory Board at Gem Pharmaceuticals, LLC and served as a Director of Ambit Biosciences Corporation. Dr. Zukiwski holds a bachelor’s degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.

James E. Goldschmidt, Ph.D. Dr. Goldschmidt joined CASI Pharmaceuticals in April 2016 as Senior Vice President of Business Development. Dr. Goldschmidt brings more than 25 years of commercial and business development experience in the biotechnology and pharmaceutical sectors. Before joining CASI, Dr. Goldschmidt held senior positions at several public and private biopharmaceutical companies, most recently as Chief Operating Officer at Macrophage Therapeutics. Prior, he was Vice President of Business Development at ImmuneXcite, an immuno-oncology biotech based in Lexington, MA. From 2007 to 2013, Dr. Goldschmidt was Vice President of Business and Commercial Development at TetraLogic Pharmaceuticals, where he lead business development and supported the company’s Initial Public Offering (IPO). Earlier in his career, Dr. Goldschmidt held several roles of increasing responsibility at Johnson & Johnson, Wyeth Pharmaceuticals, and SmithKline Beecham. Dr. Goldschmidt has had direct leadership responsibility for the development, pre-launch, launch and brand marketing of numerous oncology and specialty products over the course of his career, including the products Velcade®, Yondelis®, Mylotarg®, Torisel®, Hycamtin®, and Doxil®. Dr. Goldschmidt is a graduate of Villanova University and went on to receive a master’s degree from Drexel University and a Ph.D. from Temple University School of Medicine.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Poster

This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.